David W. Nassif Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David W. Nassif.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David W. Nassif. David W. Nassif is a EVP and CFO in SteadyMed Ltd. ($STDY) and a Chief Financial Officer in Sio Gene Therapies Inc. ($AXON) and a Principal Financial Officer in Axovant Gene Therapies Ltd. ($AXON).
Address: C/O STEADYMED THERAPEUTICS, INC 2410 CAMINO RAMON SAN RAMON 94583 CA
Companies in which David W. Nassif is an Insider
Sio Gene Therapies Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of David W. Nassif: Chief Financial Officer, Principal Financial Officer
Holdings: 34,004 shares
Current Value: $441,032
Latest Transaction: Apr 19 2021
$AXON Market Capitalization: $1.28B
$AXON Previous Close: $12.97
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
SteadyMed Ltd.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of David W. Nassif: EVP and CFO
Holdings: 0 shares
Current Value: $0
Latest Transaction: Sep 04 2018
$STDY Market Capitalization: $68.47M
$STDY Previous Close: $3.10
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of David W. Nassif
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | A | 2.47 | 239,000 | 590,330 | 239,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | A | 2.47 | 239,000 | 590,330 | 239,000 | |
| Mar 22 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | D | 0.00 | 15,060 | 0 | 0 | |
| Mar 22 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Grant | A | 0.00 | 15,060 | 0 | 34,004 | 18.9 K to 34 K (+79.50 %) |
| Jun 15 2020 | AXON | Axovant Gene Thera ... | Nassif David W. | Principal Financial ... | Option Exercise | D | 0.00 | 15,060 | 0 | 15,060 | |
| Jun 15 2020 | AXON | Axovant Gene Thera ... | Nassif David W. | Principal Financial ... | Payment of Exercise | F | 3.25 | 5,266 | 17,115 | 18,944 | 24.2 K to 18.9 K (-21.75 %) |
| Jun 15 2020 | AXON | Axovant Gene Thera ... | Nassif David W. | Principal Financial ... | Grant | A | 0.00 | 15,060 | 0 | 24,210 | 9.2 K to 24.2 K (+164.59 %) |